English
简体中文
Total: £ 56.28
Published Date: 2026-04-07 | Pages: 116 | Tables: 114 | Pharma & Healthcare
The global Biosimilar market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original "innovator" products and can manufactured when the original product"s patent expires. Reference to the innovator product is an integral component of the approval.
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilar, must maintain consistent quality and clinical performance throughout their lifecycle.
In this report is a biologic defined as proteins, peptides, hormones or antibody’s drugs production by bio-engineered technology, but does not include a vaccine.
China’s core biosimilar players include Qilu Pharmaceutical, Shanghai Henlius and 3SBIO etc. The top 3 companies only hold a share about 61%.
In terms of product, biosimilar monoclonal antibodies is the largest segment, with a share about 85%. And in terms of application, the largest application is cancer，with a share about 50%.
This report delivers a comprehensive overview of the global Biosimilar market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Biosimilar. The Biosimilar market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Biosimilar market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Biosimilar manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Biosimilar companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Biosimilar Monoclonal Antibodies
1.2.3 Biosimilar Insulin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Biosimilar Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Cancer
1.3.3 Immunological Diseases
1.3.4 Diabetes
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar Market Perspective (2021–2032)
2.2 Global Biosimilar Growth Trends by Region
2.2.1 Global Biosimilar Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Biosimilar Historic Market Size by Region (2021–2026)
2.2.3 Biosimilar Forecasted Market Size by Region (2027–2032)
2.3 Biosimilar Market Dynamics
2.3.1 Biosimilar Industry Trends
2.3.2 Biosimilar Market Drivers
2.3.3 Biosimilar Market Challenges
2.3.4 Biosimilar Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar Players by Revenue
3.1.1 Global Top Biosimilar Players by Revenue (2021–2026)
3.1.2 Global Biosimilar Revenue Market Share by Players (2021–2026)
3.2 Global Top Biosimilar Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Biosimilar Revenue
3.4 Global Biosimilar Market Concentration Ratio
3.4.1 Global Biosimilar Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar Revenue in 2025
3.5 Global Key Players of Biosimilar Head Offices and Areas Served
3.6 Global Key Players of Biosimilar, Products and Applications
3.7 Global Key Players of Biosimilar, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Biosimilar Breakdown Data by Type
4.1 Global Biosimilar Historic Market Size by Type (2021–2026)
4.2 Global Biosimilar Forecasted Market Size by Type (2027–2032)
5 Biosimilar Breakdown Data by Application
5.1 Global Biosimilar Historic Market Size by Application (2021–2026)
5.2 Global Biosimilar Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Biosimilar Market Size (2021–2032)
6.2 North America Biosimilar Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Biosimilar Market Size by Country (2021–2026)
6.4 North America Biosimilar Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar Market Size (2021–2032)
7.2 Europe Biosimilar Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Biosimilar Market Size by Country (2021–2026)
7.4 Europe Biosimilar Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar Market Size (2021–2032)
8.2 Asia-Pacific Biosimilar Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Biosimilar Market Size by Region (2021–2026)
8.4 Asia-Pacific Biosimilar Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Biosimilar Market Size (2021–2032)
9.2 Latin America Biosimilar Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Biosimilar Market Size by Country (2021–2026)
9.4 Latin America Biosimilar Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar Market Size (2021–2032)
10.2 Middle East & Africa Biosimilar Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Biosimilar Market Size by Country (2021–2026)
10.4 Middle East & Africa Biosimilar Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Qilu Pharmaceutical
11.1.1 Qilu Pharmaceutical Company Details
11.1.2 Qilu Pharmaceutical Business Overview
11.1.3 Qilu Pharmaceutical Biosimilar Introduction
11.1.4 Qilu Pharmaceutical Revenue in Biosimilar Business (2021–2026)
11.1.5 Qilu Pharmaceutical Recent Development
11.2 Bio-Thera
11.2.1 Bio-Thera Company Details
11.2.2 Bio-Thera Business Overview
11.2.3 Bio-Thera Biosimilar Introduction
11.2.4 Bio-Thera Revenue in Biosimilar Business (2021–2026)
11.2.5 Bio-Thera Recent Development
11.3 Zhejiang Hisun
11.3.1 Zhejiang Hisun Company Details
11.3.2 Zhejiang Hisun Business Overview
11.3.3 Zhejiang Hisun Biosimilar Introduction
11.3.4 Zhejiang Hisun Revenue in Biosimilar Business (2021–2026)
11.3.5 Zhejiang Hisun Recent Development
11.4 Shanghai Henlius
11.4.1 Shanghai Henlius Company Details
11.4.2 Shanghai Henlius Business Overview
11.4.3 Shanghai Henlius Biosimilar Introduction
11.4.4 Shanghai Henlius Revenue in Biosimilar Business (2021–2026)
11.4.5 Shanghai Henlius Recent Development
11.5 Innovent Biologics
11.5.1 Innovent Biologics Company Details
11.5.2 Innovent Biologics Business Overview
11.5.3 Innovent Biologics Biosimilar Introduction
11.5.4 Innovent Biologics Revenue in Biosimilar Business (2021–2026)
11.5.5 Innovent Biologics Recent Development
11.6 Jiangsu Hengrui
11.6.1 Jiangsu Hengrui Company Details
11.6.2 Jiangsu Hengrui Business Overview
11.6.3 Jiangsu Hengrui Biosimilar Introduction
11.6.4 Jiangsu Hengrui Revenue in Biosimilar Business (2021–2026)
11.6.5 Jiangsu Hengrui Recent Development
11.7 Gan&Lee
11.7.1 Gan&Lee Company Details
11.7.2 Gan&Lee Business Overview
11.7.3 Gan&Lee Biosimilar Introduction
11.7.4 Gan&Lee Revenue in Biosimilar Business (2021–2026)
11.7.5 Gan&Lee Recent Development
11.8 Tonghua Dongbao
11.8.1 Tonghua Dongbao Company Details
11.8.2 Tonghua Dongbao Business Overview
11.8.3 Tonghua Dongbao Biosimilar Introduction
11.8.4 Tonghua Dongbao Revenue in Biosimilar Business (2021–2026)
11.8.5 Tonghua Dongbao Recent Development
11.9 United Laboratory
11.9.1 United Laboratory Company Details
11.9.2 United Laboratory Business Overview
11.9.3 United Laboratory Biosimilar Introduction
11.9.4 United Laboratory Revenue in Biosimilar Business (2021–2026)
11.9.5 United Laboratory Recent Development
11.10 3SBIO
11.10.1 3SBIO Company Details
11.10.2 3SBIO Business Overview
11.10.3 3SBIO Biosimilar Introduction
11.10.4 3SBIO Revenue in Biosimilar Business (2021–2026)
11.10.5 3SBIO Recent Development
11.11 Luye Pharma
11.11.1 Luye Pharma Company Details
11.11.2 Luye Pharma Business Overview
11.11.3 Luye Pharma Biosimilar Introduction
11.11.4 Luye Pharma Revenue in Biosimilar Business (2021–2026)
11.11.5 Luye Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Biosimilar Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Biosimilar Monoclonal Antibodies
Table 3. Key Players of Biosimilar Insulin
Table 4. Key Players of Others
Table 5. Global Biosimilar Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Biosimilar Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Biosimilar Market Size by Region (US$ Million), 2021–2026
Table 8. Global Biosimilar Market Share by Region (2021–2026)
Table 9. Global Biosimilar Forecasted Market Size by Region (US$ Million), 2027–2032
Table 10. Global Biosimilar Market Share by Region (2027–2032)
Table 11. Biosimilar Market Trends
Table 12. Biosimilar Market Drivers
Table 13. Biosimilar Market Challenges
Table 14. Biosimilar Market Restraints
Table 15. Global Biosimilar Revenue by Players (US$ Million), 2021–2026
Table 16. Global Biosimilar Market Share by Players (2021–2026)
Table 17. Global Top Biosimilar Players by Tier (Tier 1, Tier 2, and Tier 3), based on Biosimilar Revenue, 2025
Table 18. Ranking of Global Top Biosimilar Companies by Revenue (US$ Million) in 2025
Table 19. Global 5 Largest Players Market Share by Biosimilar Revenue (CR5 and HHI), 2021–2026
Table 20. Global Key Players of Biosimilar, Headquarters and Area Served
Table 21. Global Key Players of Biosimilar, Products and Applications
Table 22. Global Key Players of Biosimilar, Date of General Availability (GA)
Table 23. Mergers and Acquisitions, Expansion Plans
Table 24. Global Biosimilar Market Size by Type (US$ Million), 2021–2026
Table 25. Global Biosimilar Revenue Market Share by Type (2021–2026)
Table 26. Global Biosimilar Forecasted Market Size by Type (US$ Million), 2027–2032
Table 27. Global Biosimilar Revenue Market Share by Type (2027–2032)
Table 28. Global Biosimilar Market Size by Application (US$ Million), 2021–2026
Table 29. Global Biosimilar Revenue Market Share by Application (2021–2026)
Table 30. Global Biosimilar Forecasted Market Size by Application (US$ Million), 2027–2032
Table 31. Global Biosimilar Revenue Market Share by Application (2027–2032)
Table 32. North America Biosimilar Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. North America Biosimilar Market Size by Country (US$ Million), 2021–2026
Table 34. North America Biosimilar Market Size by Country (US$ Million), 2027–2032
Table 35. Europe Biosimilar Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. Europe Biosimilar Market Size by Country (US$ Million), 2021–2026
Table 37. Europe Biosimilar Market Size by Country (US$ Million), 2027–2032
Table 38. Asia-Pacific Biosimilar Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 39. Asia-Pacific Biosimilar Market Size by Region (US$ Million), 2021–2026
Table 40. Asia-Pacific Biosimilar Market Size by Region (US$ Million), 2027–2032
Table 41. Latin America Biosimilar Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Latin America Biosimilar Market Size by Country (US$ Million), 2021–2026
Table 43. Latin America Biosimilar Market Size by Country (US$ Million), 2027–2032
Table 44. Middle East & Africa Biosimilar Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Middle East & Africa Biosimilar Market Size by Country (US$ Million), 2021–2026
Table 46. Middle East & Africa Biosimilar Market Size by Country (US$ Million), 2027–2032
Table 47. Qilu Pharmaceutical Company Details
Table 48. Qilu Pharmaceutical Business Overview
Table 49. Qilu Pharmaceutical Biosimilar Product
Table 50. Qilu Pharmaceutical Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 51. Qilu Pharmaceutical Recent Development
Table 52. Bio-Thera Company Details
Table 53. Bio-Thera Business Overview
Table 54. Bio-Thera Biosimilar Product
Table 55. Bio-Thera Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 56. Bio-Thera Recent Development
Table 57. Zhejiang Hisun Company Details
Table 58. Zhejiang Hisun Business Overview
Table 59. Zhejiang Hisun Biosimilar Product
Table 60. Zhejiang Hisun Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 61. Zhejiang Hisun Recent Development
Table 62. Shanghai Henlius Company Details
Table 63. Shanghai Henlius Business Overview
Table 64. Shanghai Henlius Biosimilar Product
Table 65. Shanghai Henlius Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 66. Shanghai Henlius Recent Development
Table 67. Innovent Biologics Company Details
Table 68. Innovent Biologics Business Overview
Table 69. Innovent Biologics Biosimilar Product
Table 70. Innovent Biologics Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 71. Innovent Biologics Recent Development
Table 72. Jiangsu Hengrui Company Details
Table 73. Jiangsu Hengrui Business Overview
Table 74. Jiangsu Hengrui Biosimilar Product
Table 75. Jiangsu Hengrui Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 76. Jiangsu Hengrui Recent Development
Table 77. Gan&Lee Company Details
Table 78. Gan&Lee Business Overview
Table 79. Gan&Lee Biosimilar Product
Table 80. Gan&Lee Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 81. Gan&Lee Recent Development
Table 82. Tonghua Dongbao Company Details
Table 83. Tonghua Dongbao Business Overview
Table 84. Tonghua Dongbao Biosimilar Product
Table 85. Tonghua Dongbao Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 86. Tonghua Dongbao Recent Development
Table 87. United Laboratory Company Details
Table 88. United Laboratory Business Overview
Table 89. United Laboratory Biosimilar Product
Table 90. United Laboratory Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 91. United Laboratory Recent Development
Table 92. 3SBIO Company Details
Table 93. 3SBIO Business Overview
Table 94. 3SBIO Biosimilar Product
Table 95. 3SBIO Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 96. 3SBIO Recent Development
Table 97. Luye Pharma Company Details
Table 98. Luye Pharma Business Overview
Table 99. Luye Pharma Biosimilar Product
Table 100. Luye Pharma Revenue in Biosimilar Business (US$ Million), 2021–2026
Table 101. Luye Pharma Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
Table 105. Authors List of This Report
List of Figures
Figure 1. Biosimilar Picture
Figure 2. Global Biosimilar Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Biosimilar Market Share by Type: 2025 vs 2032
Figure 4. Biosimilar Monoclonal Antibodies Features
Figure 5. Biosimilar Insulin Features
Figure 6. Others Features
Figure 7. Global Biosimilar Market Size by Application (US$ Million), 2021–2032
Figure 8. Global Biosimilar Market Share by Application: 2025 vs 2032
Figure 9. Cancer Case Studies
Figure 10. Immunological Diseases Case Studies
Figure 11. Diabetes Case Studies
Figure 12. Others Case Studies
Figure 13. Biosimilar Report Years Considered
Figure 14. Global Biosimilar Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Biosimilar Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Biosimilar Market Share by Region: 2025 vs 2032
Figure 17. Global Biosimilar Market Share by Players in 2025
Figure 18. Global Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Biosimilar Revenue in 2025
Figure 20. North America Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Biosimilar Market Share by Country (2021–2032)
Figure 22. United States Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Biosimilar Market Share by Country (2021–2032)
Figure 26. Germany Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Biosimilar Market Share by Region (2021–2032)
Figure 34. China Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Biosimilar Market Share by Country (2021–2032)
Figure 42. Mexico Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Biosimilar Market Share by Country (2021–2032)
Figure 46. Israel Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Biosimilar Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Qilu Pharmaceutical Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 50. Bio-Thera Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 51. Zhejiang Hisun Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 52. Shanghai Henlius Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 53. Innovent Biologics Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 54. Jiangsu Hengrui Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 55. Gan&Lee Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 56. Tonghua Dongbao Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 57. United Laboratory Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 58. 3SBIO Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 59. Luye Pharma Revenue Growth Rate in Biosimilar Business (2021–2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
